Pharmacotherapy of hypertension in patients with diabetes mellitus

Bibliography

• HERLITZ J: How to improve the cardiac prognosis for diabetes. Diabetes Care (1999) 22 (Supp1.2):B89–B96.
   Google Scholar
• FAGAN TC, DEEDWANIA PC: The cardiovascular dysmetabolic syndrome. Am. Med. (1998) 105(1A):77S–82S.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. (UKPDS 38). Br Med .j (1998) 317:703–713.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–53.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDYGROUP: Efficacy of atenolol and captopril in reducing risk of both macrovascular and microvascular complications in Type 2 diabetes (UKPDS 39). Br Med. J(1998) 317:713–720.
   PubMedGoogle Scholar
• HAFFNER SM: Epidemiology of Type 2diabetes: risk factors. Diabetes Care (1998) 21 (Supp1.3):C3–C6.
   Google Scholar
• TARNOW L, ROSSING P, GALL M-A et al.: Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care (1994) 17:1247–1251.
   PubMed Web of Science ®Google Scholar
• HYPERTENSION IN DIABETES STUDY (HDS): I. Prevalence of hypertension in newly presenting Type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. Hypertension (1993) 11:309–317.
   Google Scholar
• BURT VL, WHELTON P, ROCCELLA EJ et al: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–91. Hypertension (1995) 25:305–313.
   Google Scholar
• DESTAFANO E FORD ES, NEWMAN J, et al: Risk factors for coronary heart disease mortality among persons with diabetes. Ann. Epidemiol (1993) 3:27–34.
   PubMedGoogle Scholar
• CRIQUI MH: Epidemiology of atherosclerosis: an updated overview. Am. Cardiol (1986) 57:18C–23C.
   Google Scholar
• WILSON PW: An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Framingham Heart Study. Am. j Cardiol (1997) 80(9B):3J–8J.
   Google Scholar
• THE NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM WORKING GROUP: National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension (1994) 23:145–58.
   PubMed Web of Science ®Google Scholar
• SYSTOLIC HYPERTENSION IN EUROPE TRIAL INVESTIGATORS: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl. j Med. (1999) 340:677–684.
   PubMed Web of Science ®Google Scholar
• RITZ E, RYCHLIK I, LOCATELLI F, HALIMI S: End-stage renal failure in Type 2 diabetes: A medical catastrophe of worldwide dimensions. Am. j Kidney Dis. (1999) 34:795–808.
   PubMed Web of Science ®Google Scholar
• SHEPARD DS & HODGKIN D: Cost effectiveness of intensive treatment of hypertension. Based on presentations by Am. j Manag. Care (1998) 4(12 Supp9:5765–769; discussion S770.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with Type 2 diabetes: (UKPDS 40). Br Med. J (1998) 12:317(716072072–72076.
   Google Scholar
• ELLIOTT WJ, WEIR DR, BLACK HR: Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. (2000) 8;160(9):1277–1283.
   Google Scholar
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. (1997) 157:2413–2446.
   Google Scholar
• PRENCIPE M, CASINI AR, SANTINI M,FERRETTI C, SCALDAFERRI N, CULASSO F: Prevalence, awareness, treatment and control of hypertension in the elderly: results from a population survey. J. Hum. Hypertens. (2000) 14:825–830.
   PubMed Web of Science ®Google Scholar
• KJELDSEN SE, DAHLOF B, RB et al.: Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am. J. Hypertens. (2000) 13:899–906.
   PubMed Web of Science ®Google Scholar
• ADA: Standard of medical care for patients with diabetes mellitus. Diabetes Care (2001) 24\(Suppl. 1):53–543.
   Google Scholar
• 1999 Canadian recommendations for the management of hypertension. CMAJ(1999) 161\(Suppl. 12):S1–517.
   Google Scholar
• GAINER JV, MORROW JD, A, KING DJ, BROWN NJ: Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting-Enzyme Inhibitor in Normotensive and Hypertensive Subjects. N Engl. I Med. (1998) 339:1285–1292.
   PubMed Web of Science ®Google Scholar
• WRIGHT JM: Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers. CMAJ(2000) 163(2):188–192.
   PubMed Web of Science ®Google Scholar
• HANSSON L, LINDHOLM LH, NISKANEN L et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 353:611–616.
   PubMed Web of Science ®Google Scholar
• THE HEART OUTCOMES EVALUATION STUDY INVESTIGATORS: Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• GALLETTI F, STRAZZULLO P, CAPALDO B et al.: Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS).j Hypertens. (1999)17:439–445.
   Google Scholar
• BULLER GK, PERAZELLA M: ACE inhibitor-induced hypoglycaemia. Am. Med. (1991) 91:104–105.
   PubMed Web of Science ®Google Scholar
• HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253–259.
   PubMed Web of Science ®Google Scholar
• REARDON LC, MACPHERSON DS: Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch. Intern. Med. (1998) 12:158(1):26–32.
   Google Scholar
• GOODFRIEND TL, ELLIOTT ME, CATT KJ: Drug Therapy: Angiotensin receptors and their antagonists. N Engl. Med. (1996) 334:1649–1654.
   PubMed Web of Science ®Google Scholar
• WRIGHT JM: Choosing a first-line drug inthe management of elevated blood pressure: what is the evidence? 3: angiotensin-converting-enzyme, ACE inhibitors. CMAJ (2000) 163:293–296.
   PubMed Web of Science ®Google Scholar
• WARNER KK, VISCONTI JA, TSCHAMPEL MM: Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann. Pharmacother. (2000) 34:526–528.
   PubMed Web of Science ®Google Scholar
• GROSSMAN E: Angiotensin II receptor Blockers. Arch. Intern. Med. (2000) 160:1905–1911.
   PubMedGoogle Scholar
• BAKRIS GL, SIOMOS M, D, et al.: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int. (2000) 58:2084–2092.
   Google Scholar
• PIEPHO RW: Overview of the angiotensin-converting-enzyme inhibitors. Am. I Health Syst. Pharm. (2000) 1:57\(Supp1.1):S3S–7.
   Google Scholar
• SHAH S, KHATRI I, FREIS ED: Mechanism of antihypertensive effect of thiazide diuretics. Am. Heart J. (1978) 95(5):611–618.
   PubMed Web of Science ®Google Scholar
• WEIDMANN PO, BOEHLEN L, DE COURTEN M: Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am. Heart J. (1993) 125:1498–1513.
   PubMed Web of Science ®Google Scholar
• SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM COOPERATIVE RESEARCH GROUP: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA (1996) 276:1886–1892.
   PubMed Web of Science ®Google Scholar
• KOSTIS JB, BERGE KG, DAVIS BR, HAWKINS CM, PROBSTFIELD J: Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am. I Hypertens. (1995) 8(12 PT 1):1147–1153.
   Google Scholar
• WARRANT J, LAFFEL LM, VALSANIA P et al.: Excess mortality associated with diuretic therapy in diabetes mellitus. Arch. Intern. Med. (1991) 151:1350–1356.
   PubMedGoogle Scholar
• SISCOVICK DS, RAGHUNATHAN TE, PSATY BM, et al.: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl. J. Med. (1994) 330:1852–1857.
   Google Scholar
• ZUANETTI G LATINI R: Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. I Diabet. Complications (1997) 11:131–136.
   PubMed Web of Science ®Google Scholar
• GRESS TW, NIETO J, SHAHAR I, BRANCATI FL: Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. For the atherosclerosis risk in communities study. N Engl. J. Med. (2000) 342:905–912.
   PubMed Web of Science ®Google Scholar
• VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP ON ANTIHYPERTENSIVE AGENTS: Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension (1985) 7:1008–1016.
   Google Scholar
• RAVID M, BROTH D, LEVI Z et al: Useof enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus. A randomised, controlled trial. Ann. Intern. Med. (1998) 128:982–988.
   PubMed Web of Science ®Google Scholar
• DEACON SP, BARNETT D: Comparisonof atenolol and propranolol during insulin-induced hypoglycaemia. Br Med. J. (1976) 2:272–273.
   PubMedGoogle Scholar
• KERR D, MACDONALD IA, HELLER SR et al: Beta-adrenoceptor blockade and.Pharmacol (1990) 29:264–270.
   Google Scholar
• HIRSCH IB, BOYLE PJ, CRAFTS, PE: Higher glycaemic thresholds for symptoms during beta-adrenergic blockade in IDDM. Diabetes (1991) 40(9):1177–1186.
   PubMed Web of Science ®Google Scholar
• LYNGSOE J, SORENSEN M, SJOSTRAND H etal.: The effect of sustained release verapamil on glucose metabolism in patients with NIDDM. Drugs (1992) 1:85–87.
   Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS SG et al: Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• ESTACIO RO, JEFFERS BW, HIATT WR et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Eng]. J. Med. (1998) 338:645–652.
   PubMed Web of Science ®Google Scholar
• TATTI P, PAHOR M, BYINGTON: Outcome results of the fosinopril versus amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. (1998) 21:597–603.
   PubMed Web of Science ®Google Scholar
• MESSERLI FH, OPARIL S, FENG Z: Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazeprifi with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am. J. Cardiol (2000) 86:1182–1187.
   PubMed Web of Science ®Google Scholar
• LITHELL HO: Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am. J. Hyperterts. (1996) 9:150S–154S.
   Google Scholar
• ANDERSEN P, SELJEFLOT I, HERZOG A: Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-age men. J. Cardiovasc. Pharmacy]. (1998) 31:677–683.
   PubMed Web of Science ®Google Scholar
• THE ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Major cardiovascular events in hypertensive patients randomised to doxazosin vs. chlorthalidone. JAMA (2000) 283:1967–1975.
   Google Scholar
• BAUER JH, JONES LB, GADDY P: Effects of prazosin therapy on blood pressure, renal function, and body fluid. Arch. Intern. Med. (1984) 114:1196–1200.
   Google Scholar
• LEENEN FHH, SMITH DL, FARAKS RM, REEVES RA, MARQUEZ-JULIO A: Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive patients. Am. J. Med. (1987) 82:969–978.
   PubMed Web of Science ®Google Scholar
• LIEBSON PR, GRANDITS GA, DIANZUMBA S: Comparison of 5 antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study. Circulation (1995) 91:698–706.
   PubMed Web of Science ®Google Scholar
• GOTTDIENER JS, REDA DJ, MASSIEBM: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation (1997) 95:2007–2014.
   PubMed Web of Science ®Google Scholar
• IA0 Y, HUSAIN A: The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can.j Cardiol. (1995) 11\(Suppl. 9:13F–19F.
   Google Scholar
• MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med. J. (2000) 321(7274):1440–1444.
   PubMed Web of Science ®Google Scholar
• LACOURCIERE Y, BELANGER A, GODIN C etal.: Long-term comparison of losartan and enalapril on kidney function in hypertensive Type 2 diabetics with early nephropathy. Kidney Int. (2000) 58(2):762–769.
   Google Scholar
• POHL M, COOPER M, ULREY J, PAULSJ, ROHSE R: Safety and efficacy of irbesartan in hypertensive patients with Type 2 diabetes and proteinuria. Am. J. Hyperterts. (1997) 10:105A (Abstract).
   Google Scholar
• ESTACIO RO, JEFFERS, BW, GIFFORD N, DCHRIER RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care (2000) 23:(Suppl. 2): B54–B64.
   Google Scholar
• LINDHOLM LH, HANSSON L, EKBOM T et al.: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J. Hypertens. (2000) 18(11):1671–1675.
   Google Scholar
• LENNART HANSSON, LARS H LINDHOLM, TORD EKBOM et al. FOR THE STOP-HYPERTENSION-2 STUDY GROUP: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 354: 1751-1756.
   Google Scholar
• HANSSON L, HEDNER T, LUND-JOHANSEN P et al. FOR THE NORDIL STUDY GROUP: Randomised trial of effects of calcium antagonists compared with diuretics and P-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet (2000) 356:359–365.
   PubMed Web of Science ®Google Scholar
• BROWN MJ, PALMER CR, CASTAIGNE A et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet (2000) 356:366–372.
   Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Eng]. J. Med. (1993) 329:1456–1462.
   PubMed Web of Science ®Google Scholar
• RAVID M, BROTH D, LEVI Z et al.: Use of enalapril to attenuate decline in renal function in normotensive, normo-albuminuric patients with Type 2 diabetes mellitus. A randomised, controlled trial. Ann. Intern. Med. (1998) 128:982–988.
   PubMed Web of Science ®Google Scholar
• RAVID M, SAVIN H, JUTRIN I, BENTAL T, KATZ B, LISHNER M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive Type II diabetic patients. Ann. Intern. Med. (1993) 118:577–581.
   PubMed Web of Science ®Google Scholar
• MOGENSEN CE: Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J. (1994) 72\(Suppl. 3):S38–S45.
   Google Scholar
• PETERSON JC, ADLER S, BURKART JM et al: Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann. Intern. Med. (1995) 123:754–762.
   PubMed Web of Science ®Google Scholar
• LAZARUS JM, BOURGOIGNIE JJ, VM et al. FOR THE MODIFICATION OF DIET IN RENAL DISEASE STUDY GROUP: Achievement and safety of low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension (1997) 29:641–50.
   PubMed Web of Science ®Google Scholar
• LUSCHER TF, WAEBER B: Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomised trial. ..J. Cardiovasc. Pharmacol (1993) 21(2):305–309.
   PubMed Web of Science ®Google Scholar
• PITTROW DB, ANTLSPERGER A, WELZEL D, WAMBACH G, SCHARDT W, WEIDINGER G: Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. Cardiovasc. Drugs net: (1997) 11(5):619–627.
   PubMed Web of Science ®Google Scholar
• PLAT E SAINI R: Management of hypertension: the role of combination therapy. Am. j Hypertens. (1997) 10 (2):262S-271s.
   Google Scholar
• CORCORAN JS, PERKINS JE, HOFFBRAND BI, YUDKIN JS: Treating hypertension in non-insulin-dependent: a comparison of atenolol, nifedipine, and captopril combined with bendrofluazide. Diabet. Med. (1987) 4(2):164–168.
   PubMed Web of Science ®Google Scholar
• SHIGIHARA T, SATO A, HAYASHI K, SARUTA T: Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with Type II diabetes. Hyperteris. Res. (2000) 23(3):219–226.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, WEIR MR, DEQUATTRO, MCMAHON FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. (1998) 54(4):1283–1289.
   PubMed Web of Science ®Google Scholar
• SOUVIRON RODRIGUEZ A, MARTINEZ MORILLO M: Captopril + hydrochlorothiazide versus captopril + nifedipine in the treatment of arterial hypertension in diabetes mellitus Type II. Rev Esp. Cardiol (1992) 45(7):432–437. (Abstract - Article in Spanish)
   Google Scholar
• SCHNEIDER M, LERCH M, PAPIRI M, et al.: Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone in hypertensive Type 2 diabetes.. (1996) 14(5):669–677.
   Google Scholar
• SHEINFELD GR, BAKRIS GL: Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am.. (1999) 12(8 Pt. 2):805–855.
   Google Scholar
• STAMLER J, VACCARO 0, NEATON JD, WENTWORTH D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care (1993) 16:434–444.
   PubMed Web of Science ®Google Scholar
• SNIDERMAN A, MICHEL C, RACINE N: Heart disease in patients with diabetes mellitus. j Clin. Epidemiol (1992) 45:1357–1370.
   PubMed Web of Science ®Google Scholar